BSX · News · 20260811N

Capital Return Program

BOSTON SCIENTIFIC CORP · 2026-08-11 · Importance 64 · Surprise 42

Boston Scientific authorized a $5 billion share-repurchase program following its second-quarter 2026 results. The authorization was cited alongside quarterly revenue of $5.44 billion and adjusted EPS of $0.86. The digest does not specify the program’s expiration date, execution timing, or repurchase amount completed to date.

Key facts

• Handelsbanken Fonder AB reduced its stake in BOSTON SCIENTIFIC CORP by 38.8%, selling 1,002,628 shares and retaining 1.58 million shares valued at $67.6 million. source
• Insiders purchased approximately $9.9 million worth of BOSTON SCIENTIFIC CORP shares in the last three months. source
• BOSTON SCIENTIFIC CORP EVP and CFO Jonathan Monson acquired 9,908 shares on August 10, 2026 at $50.46 per share via discretionary 401(k) rebalancing and now indirectly holds 9,908 shares and directly holds 39,063 shares. source
• Institutional investors hold 89.07% of BOSTON SCIENTIFIC CORP. source